Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System

Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of adoptively transferred CAR T cells, antigen-n...

Full description

Saved in:

Bibliographic Details
Published in:	Cell reports (Cambridge) Vol. 23; no. 7; pp. 2130 - 2141
Main Authors:	Avanzi, Mauro P., Yeku, Oladapo, Li, Xinghuo, Wijewarnasuriya, Dinali P., van Leeuwen, Dayenne G., Cheung, Kenneth, Park, Hyebin, Purdon, Terence J., Daniyan, Anthony F., Spitzer, Matthew H., Brentjens, Renier J.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 15.05.2018
Subjects:	adoptive transfer Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use armored CAR Autocrine Communication - drug effects B-ALL B-Lymphocytes - drug effects CAR T cell Cell Proliferation - drug effects Cell Survival - drug effects chimeric antigen receptor Disease Models, Animal Humans IL-18 Immune System - drug effects Immune System - metabolism Immunotherapy Immunotherapy, Adoptive interleukin-18 Interleukin-18 - metabolism Mice, Inbred C57BL Mice, SCID MUC16 Neoplasms - drug therapy Neoplasms - immunology Neoplasms - pathology ovarian cancer Signal Transduction - drug effects T-Lymphocytes - drug effects T-Lymphocytes - immunology Tumor Microenvironment - drug effects Xenograft Model Antitumor Assays armored CAR B-ALL MUC16 interleukin-18 ovarian cancer IL-18 chimeric antigen receptor adoptive transfer CAR T cell
ISSN:	2211-1247, 2211-1247
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!